Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on December 9, 2021. The report addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Roxanne S. Austin informed the Board of Directors on December 9, 2021, of her decision not to stand for re-election.
- Her current term expires at the 2022 annual shareholders meeting scheduled for April.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the status of the Board of Directors seat held by Roxanne S. Austin following the 2022 annual shareholders meeting.
- Confirm if a successor director has been nominated or appointed to fill the vacancy.
- Review the company's proxy statement for the 2022 annual meeting for details on the election process.